Suggested Remit: To appraise the clinical and cost effectiveness of rivogenlecleucel within its marketing authorisation for treating haematological non-malignant diseases in children and young people undergoing haploidentical haematopoietic stem cell transplant.
Topic is suspended
- Status:
- Suspended
- Decision:
- Prioritised
- Process:
- TA
- ID number:
- 1496
Project Team
- Project lead
- Emily Richards
Email enquiries
If you have any queries please email scopingta@nice.org.uk
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 29 January 2021 | Note added to the project documents |
| 29 January 2021 | Suspended. Topic is suspended |
| 13 May 2019 (10:00) | Scoping workshop (Manchester) |
| 20 March 2019 - 17 April 2019 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators |
| 26 June 2018 | In progress. Topic referred |
For further information on our processes and methods, please see our CHTE processes and methods manual